1-877-936-8422

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

New members of Academy for Excellence in Clinical Medicine selected

Submitted by sobecksm on

Vanderbilt University School of Medicine Academy for Excellence in Clinical Medicine (AECM) has selected 25 new members.

https://news.vumc.org/2023/12/15/new-members-of-academy-for-excellence-in-clinical-medicine-selected/
Kathy Whitney
Locked

New dean of Basic Sciences aims to take Vanderbilt to the next level in biomedical research, drug discovery

Submitted by sobecksm on
Whether working on dynamic discoveries in the lab, connecting with students and faculty or pursuing his passion for nature photography, acclaimed biomedical researcher John Kuriyan is inspired by his recent move to join Vanderbilt as the new dean of the School of Medicine Basic Sciences and Distinguished University Professor.
https://news.vanderbilt.edu/2023/04/03/new-dean-of-basic-sciences-aims-to-take-vanderbilt-to-the-next-level-in-biomedical-research-drug-discovery/
Amy Wolf
Locked

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Submitted by robbikm2 on

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

https://news.vumc.org/2023/10/04/vulnerability-found-in-immunotherapy-resistant-triple-negative-breast-cancer/
Tom Wilemon
Locked

SPORE in Breast Cancer

SPORE in GI Cancer
Read More

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving neratinib in addition to normal therapy may work better in treating cancer than the endocrine therapy patients would normally receive.
Not Available
II
Not Available
NCT05919108
VICC-NCBRE23172
Learn More

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

Lymphoma

The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.
Lymphoma
N/A
Jallouk, Andrew
NCT05776160
VICC-XDCTT23452
Learn More

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.

Call Now
NCI Designated Cancer Center
NCCN National Comprehensive Cancer Network
NCI National Clinical Trials Network